
Article • Controversy
TAVI is approved for lower risk patients
The Medtronic CoreValve Evolut R System received its CE Mark of approval this August to treat aortic stenosis in patients with an intermediate risk for undergoing conventional surgery for a valve replacement. This is a controversial indication for transcatheter aortic valve implantations (TAVI) – one that has been eagerly sought by some clinicians but resisted by others. Younger patients will…